第一金融网主办
»您现在的位置: 第一金融网 >> 金融焦点 >> 文传商讯 >> 正文

Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies

2019/8/14 9:26:10  文章来源:文传商讯  作者:文传商讯
文章简介: NewpotentialgastrointestinalandlungcancertherapiesfromBoehringerIngelheim’sinnovativeoncologypipelinewillbecombinedwiththepatient-driven

New potential gastrointestinal and lung cancer therapies from Boehringer Ingelheim’s innovative oncology pipeline will be combined with the patient-driven drug-development capabilities at MD Anderson

The Center will initially investigate KRAS pathway inhibitors and a TRAILR2 antibody from Boehringer Ingelheim’s cancer research

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim and The University of Texas MD Anderson Cancer Centertoday announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers. The establishment of a joint Virtual Research and Development Center will enable effective data sharing and analysis between the organizations.

The partnership is built on a flexible framework, allowing for projects to enter at different stages (research, development and/or clinical stage) over several years. It further combines the unique patient-driven drug-development capabilities of MD Anderson’s Therapeutics Discovery division with the innovative pipeline of novel medicines from Boehringer Ingelheim.

MD Anderson’s Therapeutics Discovery division is a multidisciplinary team of clinicians and researchers focused on advancing the next generation of cancer therapies. As part of the division, the TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology) platform conducts cutting-edge translational research to better understand how new medicines work and which patients will see most benefit.

"We could not have chosen a better partner with all its research, translational and clinical expertise in lung and gastrointestinal cancers. Together, we hope to transform the treatment landscape for these diseases by tackling their root causes and drivers, that have so far remained elusive, exploring new and smart ways of killing cancer cells," said Dr Victoria Zazulina, Corporate Vice President and Global Head of Oncology, Medicine, at Boehringer Ingelheim. "Our innovative oncology pipeline coupled with strong partnerships like this will contribute to unravelling the complexities of these diseases and bringing innovative solutions to people with various types of cancers."

The Virtual Research and Development Center will focus on the development of potential new treatments including:

  • KRAS inhibition concepts, as mutations in the KRAS gene are common in various cancers, specifically in certain types of lung and gastrointestinal cancers.
  • a TRAILR2 agonistic antibody, with the potential to selectively induce cancer cell death (apoptosis).

“Within MD Anderson, we are committed to a singular goal of ending cancer,” said Tim Heffernan, Ph.D., executive director of TRACTION at MD Anderson. “We look forward to working with Boehringer Ingelheim to advance their innovative pipeline of cancer medicines. Our Therapeutics Discovery team is well-poised to conduct impactful translational research, and this partnership will allow us to more rapidly advance much-needed new therapies to patients.”

More than 4.1 million people die from gastrointestinal and lung cancers every year worldwide1, indicating an urgent need for new treatment approaches. Gastrointestinal cancers represent a heterogeneous complex array of diseases, and include oesophageal (throat), gastric (stomach), liver, pancreatic, and colorectal cancers. In 2018, lung cancer caused more than 1.7 million deaths1. There are two main types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-and-md-anderson-form-collaboration

For more information, visit: 
https://www.boehringer-ingelheim.com

分享到:
第一金融网免责声明:
1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
2、文章来源为均为其它媒体的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供更多信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
3、本网站所载文章、数据、网友投稿等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一金融网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
发表评论

【发表评论】(网友评论内容只代表网友观点,与本站立场无关!)
 姓 名:
 评 分: 1分 2分 3分 4分 5分
 评论内容:
验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏社会稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  香港机场取消全部航班什么时间恢复飞行?2019年
     国务院发文明确时间表 这些民生难题将限期解决
    [银行]  存入青岛农商行的500万美金竟然消失了?
     晋商银行上市背后:盈利增速收窄 曾卷入广发银行
    [股票]  人造肉真正龙头股涨停 多只个股大涨
     今日热点股票:区块链龙头股冲击涨停 数字货币受
    [基金]  大盘重回3000点 大涨底气在哪?基金最新解读来了
     A股酝酿变盘信号!公募逆势加仓,北上资金调仓换
    [保险]  人保车险理赔时间规定
     职工医保和新农合医保哪个好?主要看这三点
    [期货]  消息人士:中国考虑大幅放开期货市场 以吸引海外
     大跌4%!油价快到50美元 这是个让美国尴尬的位置
    [股评]  五大券商周三看好六大板块(8/14)
     券商评级:三大指数调整 九股迎来掘金良机(8/1
    [港股]  阿里总裁卷入史上最大财务丑闻 事件竟也波及特朗
     实控人涉嫌犯罪被采取强制措施 暴风集团开盘跌停
    [美股]  刚刚又有美股巨头暴跌400亿 股神巴菲特亏惨了
     人民币贬值致美股暴跌 道指跳水近800点 川普指中
    [外汇]  人民币对美元汇率中间价报7.0211元 下调75个基点
     人民币即期汇率开盘跌破6.95 离岸人民币跌破6.9
    [债券]  中城集团旗下多支债券违约 14亿银行存款被冻结
     中国债市:隔夜回购创近十年新低
    [黄金]  黄金疯涨!六年前血战华尔街的“中国大妈”解套
     刘智辛:欧美货币持稳,黄金日线三连阳,原油多
    [理财]  杨幂工作室声明:已停止与范思哲品牌的全部合作
     范思哲的中国危机
    [信托]  跌破8% 集合信托收益或继续下跌
     信托违约增多 预期收益9%的产品还能买吗?
    [房产]  西安经济“摔跤” 中西部城市房地产依赖度高
     二线城市房贷利率上调 房贷利率区间波动或成常态
    [汽车]  江淮汽车三十未立:各条产品线处于严重下滑状态
     王思聪晒超跑,在美国街头炸街,一脚油门,看不
  • 此栏目下没有推荐文章
  • | 设为首页 | 加入收藏 | 关于我们 | 友情链接 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2027 afinance.cn All Rights Reserved 版权所有·第一金融网 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客理财及投资指导,凡是以第一金融网名义做股票推荐的行为均属违法!

    广告商的言论与行为均与第一金融网无关!股市有风险,投资需谨慎。

    合作邮箱:fengyueyoubian@sina.com 合作电话:18678839953 点击这里给我发消息